Complexo Hospitalario Universitario De Vigo

At the Complexo Hospitalario Universitario De Vigo the neurology department leads trials aimed at evaluating new disease‑modifying therapies for multiple sclerosis and related neuro‑inflammatory conditions, seeking to slow disability progression and improve quality of life.

• Relapsing forms of multiple sclerosis
• Primary and secondary progressive multiple sclerosis
• Upper limb spasticity after stroke or traumatic brain injury
• Biomarker‑driven treatment selection for first‑episode psychosis

The neurology program encompasses 63 active trials with 65 investigators, emphasizing innovative mechanisms, patient‑centered outcomes, and long‑term safety monitoring across neurodegenerative diseases.

The site hosts a broad oncology program that tests targeted agents, immunotherapies and combination regimens in cancers such as breast cancer, ovarian cancer, non‑small cell lung cancer and prostate cancer, with the goal of improving survival and response rates.

• HER2‑positive and triple‑negative breast cancer
• BRCA‑mutated ovarian and pancreatic cancers
• Resectable and advanced non‑small cell lung cancer
• High‑risk prostate cancer with androgen deprivation therapy

Oncology investigators collaborate across surgical, medical and radiation specialties, contributing to the overall portfolio of 63 clinical trials aimed at advancing curative and maintenance strategies.

Clinical studies at the hospital address acute and chronic heart conditions, including myocardial infarction, heart failure, hypertrophic cardiomyopathy and hypertension, as well as metabolic disorders like type 2 diabetes, aiming to reduce mortality and improve cardiac function.

• Post‑myocardial infarction left ventricular dysfunction
• Symptomatic hypertrophic cardiomyopathy
• Takotsubo syndrome treatment strategies
• Cardiovascular risk reduction with lipid‑lowering agents

The cardiovascular research team leverages advanced imaging and biomarker analysis to support 63 trials, integrating cardiology expertise with metabolic disease management.

Investigators explore novel biologics and small molecules for systemic autoimmune conditions such as systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis and Sjögren’s syndrome, focusing on disease activity control and organ protection.

• Active and refractory lupus nephritis
• Early systemic lupus erythematosus
• Psoriatic arthritis with skin and joint involvement
• Sjögren’s syndrome with interstitial lung disease

Long‑term safety extensions and patient‑reported outcomes are integral to the 63‑trial portfolio, supporting a comprehensive approach to autoimmune disease management.

The research portfolio includes trials targeting bacterial infections, viral hepatitis and emerging pathogens, evaluating optimized antibiotic regimens and antiviral therapies to enhance cure rates and limit resistance.

• Pseudomonas aeruginosa bacteremia short‑course antibiotics
• Chronic hepatitis B virus infection therapies
• COVID‑19 therapeutic interventions
• Enterococcal bacteremia treatment duration studies

Leveraging the analytical and diagnostic equipment area, investigators contribute to the overall 63 clinical trials, advancing precision medicine for infectious and immune‑mediated diseases.